June 1, 2018 Issue of JAMA Oncology

June 2018, Vol 4, No. 6, Pages 759-895

Original Investigation

Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial

Erin L. Van Blarigan, ScD; Charles S. Fuchs, MD, MPH; Donna Niedzwiecki, PhD; et al.

Abstract Full Text

free access has audio

JAMA Oncol. 2018;4(6):783-790. doi:10.1001/jamaoncol.2018.0126

This cohort study of patients with stage III colon cancer enrolled in the CALGB 89803/Alliance trial evaluated the association of survival rates with adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors.

Podcast: Association of Colon Cancer Survival With ACS Guideline Adherence

Editorial
Helping Colorectal Cancer Survivors Benefit From Changing Lifestyle Behaviors: Implementation Science and Private Industry Collaboration to the Rescue
Michael J. Fisch, MD, MPH; Lorna H. McNeill, PhD, MPH; Karen M. Basen-Engquist, PhD, MPH

JAMA Oncol

Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act

Ryan D. Nipp, MD, MPH; Amy M. Shui, MA; Giselle K. Perez, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):791-797. doi:10.1001/jamaoncol.2018.0097

This population-based study analyzes cancer survivors鈥� ability to access and afford health care during implementation of the US Affordable Care Act using data from the 2010 to 2016 National Health Interview Survey.

Association of Muscle and Adiposity Measured by Computed Tomography With Survival in Patients With Nonmetastatic Breast Cancer

Bette J. Caan, DrPH; Elizabeth M. Cespedes Feliciano, ScD; Carla M. Prado, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):798-804. doi:10.1001/jamaoncol.2018.0137

This observational study examines associations of sarcopenia, muscle radiodensity, and adiposity with overall mortality in nonmetastatic breast cancer.

Invited Commentary
Obesity, Body Composition, and Breast Cancer: An Evolving Science
Elisa V. Bandera, MD, PhD; Esther M. John, PhD

JAMA Oncol

Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer

Heather Hampel, MS, CGC; Rachel Pearlman, MS, CGC; Mallory Beightol, BS, MB(ASCP); et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):806-813. doi:10.1001/jamaoncol.2018.0104

This genetic sequencing study explores whether up-front tumor sequencing can replace the prevailing paradigm for universal tumor screening for Lynch syndrome, which includes a sequence of several screening tests.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

Scott M. Schuetze, MD, PhD; Vanessa Bolejack, MPH; Dafydd G. Thomas, MD, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):814-820. doi:10.1001/jamaoncol.2018.0601

This nonrandomized, noncontrolled clinical trial evaluates the 6-month progression-free survival, tumor objective response, and overall survival rates in patients with gastrointestinal stromal tumors treated with dasatinib.

Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster

Ola Landgren, MD, PhD; Rachel Zeig-Owens, DrPH; Orsolya Giricz, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2018;4(6):821-827. doi:10.1001/jamaoncol.2018.0509

This case series assesses whether environmental exposures from the World Trade Center disaster site are associated with multiple myeloma and its precursor disease, monoclonal gammopathy of undetermined significance, in New York City firefighters.

Editorial
Some Thoughts on Exposure to the World Trade Center Wreckage and Cancer
Otis W. Brawley, MD, MACP

JAMA Oncol

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial

Jeff M. Michalski, MD, MBA; Jennifer Moughan, MS; James Purdy, PhD; et al.

Abstract Full Text

free access online only has audio

JAMA Oncol. 2018;4(6):e180039. doi:10.1001/jamaoncol.2018.0039

This randomized clinical trial assesses whether dose-escalated radiation therapy vs standard dose improves survival for men with intermediate-risk prostate cancer.

Podcast: Standard vs Dose-Escalated Radiotherapy in Medium-Risk Prostate Cancer

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Andrea Cercek, MD; Campbell S.D. Roxburgh, MD, PhD; Paul Strombom, MD; et al.

Abstract Full Text

free access online only

JAMA Oncol. 2018;4(6):e180071. doi:10.1001/jamaoncol.2018.0071

This study compares preoperative chemoradiation followed by postoperative adjuvant chemotherapy vs total neoadjuvant therapy for treatment of locally advanced rectal cancer.

Invited Commentary
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer鈥擳he New Standard of Care?
Theodore S. Hong, MD; David P. Ryan, MD

JAMA Oncol

Brief Report

Estimation of Future Cancer Burden Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster

Ankura Singh, MPH; Rachel Zeig-Owens, DrPH; William Moir, MPH; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):828-831. doi:10.1001/jamaoncol.2018.0504

This cohort study projects the future burden of cancer among rescue and recovery workers exposed to multiple carcinogenic agents during the September 11, 2001, World Trade Center attack, by estimating the 20-year cancer incidence.

Editorial
Some Thoughts on Exposure to the World Trade Center Wreckage and Cancer
Otis W. Brawley, MD, MACP

JAMA Oncol

Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program

Caitlin C. Murphy, PhD, MPH; David E. Gerber, MD, MSCS; Sandi L. Pruitt, PhD, MPH

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):832-836. doi:10.1001/jamaoncol.2017.3605

This analysis of data from the Surveillance, Epidemiology, and End Results program of cancer registries examines prevalence of prior cancer among individuals newly diagnosed with cancer.

Invited Commentary
Incident Cancer in Cancer Survivors鈥擶hen Cancer Lurks in the Background
Nancy E. Davidson, MD

JAMA Oncol

Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing

Annette S. Kim, MD, PhD; Angela N. Bartley, MD; Julia A. Bridge, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):838-841. doi:10.1001/jamaoncol.2017.4021

This data analysis compares the analytical validity of US Food and Drug Administration鈥揳pproved companion diagnostics and laboratory-developed tests for 3 genetic analytes using uniform reference materials from the College of American Pathologists Molecular Oncology Committee.

Editorial
Precision Medicine and Testing for Tumor Biomarkers鈥擜re All Tests Born Equal?
Daniel F. Hayes, MD

JAMA Oncol

Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws

Stacie B. Dusetzina, PhD; Haiden A. Huskamp, PhD; Aaron N. Winn, PhD, MPP; et al.

Abstract Full Text

free access online only

JAMA Oncol. 2018;4(6):e173598. doi:10.1001/jamaoncol.2017.3598

This analysis of health claims data from 3 large nationwide insurers examines changes in oral anticancer medication use, out-of-pocket spending, and total health plan spending associated with adoption of state parity laws.

Research Letter

Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests

Gonzalo Torga, MD; Kenneth J. Pienta, MD

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):868-870. doi:10.1001/jamaoncol.2017.4027

This cohort study examines the reliability and potential utility of 2 commercially available liquid biopsy assays for reported mutations in cell-free DNA.

Editorial
Precision Medicine and Testing for Tumor Biomarkers鈥擜re All Tests Born Equal?
Daniel F. Hayes, MD

JAMA Oncol

Oral Ketamine vs Placebo in Patients With Cancer-Related Neuropathic Pain: A Randomized Clinical Trial

Marie T. Fallon, MD; Andrew Wilcock, MD; Caroline A. Kelly, MSc; et al.

Abstract Full Text

open access

JAMA Oncol. 2018;4(6):870-872. doi:10.1001/jamaoncol.2018.0131

This multicenter randomized clinical trial compares oral ketamine with placebo for treating neuropathic pain in patients with cancer.

Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort

Roy Mano, MD; Shlomit Tamir, MD; Inbal Kedar, MSc; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):872-874. doi:10.1001/jamaoncol.2018.0271

This study evaluates the use of a comprehensive screening protocol for prostate, breast, colorectal, and pancreatic cancer and skin malignant abnormalities in male BRCA carriers.

Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study

Bo Huang, PhD; Lu Tian, ScD; Enayet Talukder, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):874-876. doi:10.1001/jamaoncol.2018.0275

This study evaluates the duration of response for crizotinib vs chemotherapy for patients with ALK-positive lung cancer using data from the PROFILE-1014 randomized clinical trial.

National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer

Kimberly K. Childers, MS, LCGC; Melinda Maggard-Gibbons, MD, MSHS; James Macinko, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):876-879. doi:10.1001/jamaoncol.2018.0340

This cross-sectional study describes the national distribution of genetic testing for hereditary cancer risk, identifies disparities, and assesses whether a gender gap exists

Physicians鈥� Compassion, Communication Skills, and Professionalism With and Without Physicians鈥� Use of an Examination Room Computer: A Randomized Clinical Trial

Ali Haider, MD; Kimberson Tanco, MD; Margeaux Epner, BA; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):879-881. doi:10.1001/jamaoncol.2018.0343

This randomized controlled crossover study compares patients鈥� perception of physicians鈥� compassion and patients鈥� perception of physicians鈥� communication skills and professionalism and patients鈥� overall physician preference after watching two standardized scripted-video vignettes of physicians.

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study

Miki Horiguchi, BPharm; Lu Tian, ScD; Hajime Uno, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):881-882. doi:10.1001/jamaoncol.2018.0518

This study compares conventional hazard ratios and an alternative, clinically interpretable approach to quantify the long-term survival benefit in patients receiving chemotherapy with immunotherapy.

Review

A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review

Julia A. Beaver, MD; Lynn J. Howie, MD; Lorraine Pelosof, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2018;4(6):849-856. doi:10.1001/jamaoncol.2017.5618

This review describes all malignant hematology and oncology accelerated approvals from inception of the US Food and Drug Administration accelerated approval program.

糖心vlog Insights

Management of Metastatic Melanoma in 2018

Howard L. Kaufman, MD; Kim Margolin, MD; Ryan Sullivan, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):857-858. doi:10.1001/jamaoncol.2018.0170

This Insights discusses management strategies for metastatic melanoma using the most recent therapeutic options.

JAMA Oncology Clinical Evidence Synopsis

Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma

Talal Hilal, MD; Jose F. Leis, MD, PhD; Craig B. Reeder, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):859-860. doi:10.1001/jamaoncol.2018.0111

This synopsis summarizes the prospective randomized clinical trials that examined the use of rituximab maintenance therapy in treatment-naive patients with follicular lymphoma after first-line induction chemoimmunotherapy.

JAMA Oncology Clinical Challenge

Erythematous Velvety Plaque of the Scrotum and Penis

Yu Xi Terence Law, BSc (Hons), MBBS, MRCS; Valerie Huei Li Gan, MBBS, MRCS, MMed (Surg), FAMS (Urology); Kae Jack Tay, MBBS, MRCS, MMed (Surg), MCI, FAMS (Urology)

Abstract Full Text

JAMA Oncol. 2018;4(6):861-862. doi:10.1001/jamaoncol.2017.4064

A 70-year-old Chinese man with a medical history of hypertension, hyperlipidaemia, and ischemic heart disease was referred to the urology clinic for 1 week of dysuria; there was a nonpruritic, erythematous, velvety plaque over the left base of his penis. What is your diagnosis?

Viewpoint

Global Cancer Clinical Trials鈥擟ooperation Between Investigators in High-Income Countries and Low- and Middle-Income Countries

Pankaj Kumar Panda, MSc; Rakesh Jalali, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):765-766. doi:10.1001/jamaoncol.2017.5856

This Viewpoint outlines an action plan to foster cooperation between cancer investigators in high-income countries and low- and middle-income countries.

Targeted Intraoperative Radiation Therapy鈥擜 Promising Option for Accelerated Partial Breast Irradiation

Amishi Bajaj, BA; Dennis R. Holmes, MD; William Small Jr, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):767-768. doi:10.1001/jamaoncol.2018.0008

This Viewpoint examines the evidence supporting the efficacy of intraoperative radiation therapy compared with other treatment modalities for patients with early-stage breast cancer.

Clinical Trials in Medical Center Advertising

Alex John London, PhD; Jonathan Kimmelman, PhD

Abstract Full Text

JAMA Oncol. 2018;4(6):769-770. doi:10.1001/jamaoncol.2018.0181

This Viewpoint evaluates whether there is benefit for medical centers to advertise the opportunity for clinical trial participation.

Editorial

Precision Medicine and Testing for Tumor Biomarkers鈥擜re All Tests Born Equal?

Daniel F. Hayes, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):773-774. doi:10.1001/jamaoncol.2017.4018

Some Thoughts on Exposure to the World Trade Center Wreckage and Cancer

Otis W. Brawley, MD, MACP

Abstract Full Text

JAMA Oncol. 2018;4(6):775-776. doi:10.1001/jamaoncol.2018.0498

Helping Colorectal Cancer Survivors Benefit From Changing Lifestyle Behaviors: Implementation Science and Private Industry Collaboration to the Rescue

Michael J. Fisch, MD, MPH; Lorna H. McNeill, PhD, MPH; Karen M. Basen-Engquist, PhD, MPH

Abstract Full Text

JAMA Oncol. 2018;4(6):777-778. doi:10.1001/jamaoncol.2018.0124

Invited Commentary

Obesity, Body Composition, and Breast Cancer: An Evolving Science

Elisa V. Bandera, MD, PhD; Esther M. John, PhD

Abstract Full Text

JAMA Oncol. 2018;4(6):804-805. doi:10.1001/jamaoncol.2018.0125

Incident Cancer in Cancer Survivors鈥擶hen Cancer Lurks in the Background

Nancy E. Davidson, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):836-837. doi:10.1001/jamaoncol.2017.4167

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer鈥擳he New Standard of Care?

Theodore S. Hong, MD; David P. Ryan, MD

Abstract Full Text

online only

JAMA Oncol. 2018;4(6):e180070. doi:10.1001/jamaoncol.2018.0070

JAMA Oncology Patient Page

Tumor Lysis Syndrome

Arjun Gupta, MD; Joseph A. Moore, MD

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):895. doi:10.1001/jamaoncol.2018.0613

This Patient Page explains tumor lysis syndrome, how it affects the body, who is at greatest risk, how to recognize it, and measures to help prevent it or treat it.

Cancer Care Chronicles

Our Shared Humanity鈥擬usic as a Means of Facilitating Conversations on End-of-Life Care

Cynthia S. Peng, BS

Abstract Full Text

JAMA Oncol. 2018;4(6):771-772. doi:10.1001/jamaoncol.2017.4186

This article discusses a case in which music was used as a platform for initiating a conversation on end-of-life care.

Comment & Response

Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening

Ryan A. Denu, BS

Abstract Full Text

JAMA Oncol. 2018;4(6):883. doi:10.1001/jamaoncol.2017.5906

Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening鈥擱eply

Dezheng Huo, MD, PhD; Charles M. Perou, PhD; Olufunmilayo I. Olopade, MBBS

Abstract Full Text

JAMA Oncol. 2018;4(6):883-884. doi:10.1001/jamaoncol.2017.5909

End-of-Life Care Options and Decision Making for Older Patients With Malignant Brain Tumors

Andrew K. Conner, MD; Robert G. Briggs, BS; Michael E. Sughrue, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):884-885. doi:10.1001/jamaoncol.2018.0001

Possible Underestimation of the Provision of Palliative Care

Hilde M. Buiting, PhD; Tjomme de Graas, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):885-886. doi:10.1001/jamaoncol.2017.5827

End-of-Life Care Options and Decision Making for Older Patients With Malignant Brain Tumors鈥擱eply

Laura L. Dover, MD; Caleb R. Dulaney, MD; Gabrielle Rocque, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):885. doi:10.1001/jamaoncol.2018.0004

Possible Underestimation of the Provision of Palliative Care鈥擱eply

Yael Schenker, MD, MAS; Robert Arnold, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):886. doi:10.1001/jamaoncol.2017.5830

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Jing Liu, MS; Jinbo Yue, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):887. doi:10.1001/jamaoncol.2018.0228

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer

Antoine Adenis, MD, PhD; Florian Lordick, MD, PhD

Abstract Full Text

JAMA Oncol. 2018;4(6):887-888. doi:10.1001/jamaoncol.2018.0239

Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer鈥擱eply

Mohan Suntharalingam, MD, MBA; Kathryn Winter, MS; David Ilson, MD, PhD

Abstract Full Text

JAMA Oncol. 2018;4(6):888-889. doi:10.1001/jamaoncol.2018.0242

Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome

Giorgio Bogani, MD, PhD; Umberto Leone Roberti Maggiore, MD, PhD; Domenica Lorusso, MD, PhD; et al.

Abstract Full Text

JAMA Oncol. 2018;4(6):889. doi:10.1001/jamaoncol.2018.0253

Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome

Manon Suerink, MD; Sanne W. ten Broeke, MD; Maartje Nielsen, MD, PhD

Abstract Full Text

JAMA Oncol. 2018;4(6):889-890. doi:10.1001/jamaoncol.2018.0256

Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome鈥擱eply

Emma J. Crosbie, PhD; Neil A. J. Ryan, MBChB; D. Gareth Evans, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):890-891. doi:10.1001/jamaoncol.2018.0280

Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia

Robert Peter Gale, MD, PhD, DSc(hc), FRSM

Abstract Full Text

JAMA Oncol. 2018;4(6):891. doi:10.1001/jamaoncol.2018.0364

Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia鈥擱eply

Hui-Sheng Ai, MD; Mei Guo, MD; Nelson J. Chao, MD

Abstract Full Text

JAMA Oncol. 2018;4(6):891. doi:10.1001/jamaoncol.2018.0367

Correction

Data Presentation Error in Results Section

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):891. doi:10.1001/jamaoncol.2018.1672

In This Issue of JAMA Oncology

Highlights

Abstract Full Text

free access

JAMA Oncol. 2018;4(6):759. doi:10.1001/jamaoncol.2017.3227

October 2024 - April 2015

Decade

Year

Issue

June 2018, Vol 4, No. 6, Pages 759-895